Kraig Biocraft Laboratories Nears Completion of Largest Production Batch of Parental Line Spider Silk Silkworms
Kraig Biocraft Laboratories (OTCQB: KBLB) announces the near completion of its largest production batch of BAM-1 parental line spider silk silkworms. This milestone marks the achievement of true commercial-scale levels of parental strain production. The current batch is cocooning this week, with the production team reporting strong growth and great colony health.
CEO Kim Thompson states this production cycle will deliver the largest supply of BAM-1 production hybrid eggs in the company's history. This success verifies the scalability of Kraig Labs' spider silk technology, positioning the company to deliver commercial quantities to partners and customers. The results will supply Kraig Labs with millions of BAM-1 production hybrids for commercial production, marking a transition from development to a true production focus.
Kraig Biocraft Laboratories (OTCQB: KBLB) annuncia il quasi completamento del suo più grande lotto di produzione di bachi da seta della linea parentale BAM-1. Questo traguardo segna il raggiungimento di veri livelli di produzione commerciale della linea parentale. L'attuale lotto è in fase di bozzolo questa settimana, con il team di produzione che riporta una forte crescita e una grande salute della colonia.
Il CEO Kim Thompson afferma che questo ciclo di produzione fornirà il più grande approvvigionamento di uova ibride di produzione BAM-1 nella storia dell'azienda. Questo successo verifica la scalabilità della tecnologia della seta di ragno di Kraig Labs, posizionando l'azienda per fornire quantità commerciali a partner e clienti. I risultati forniranno a Kraig Labs milioni di ibridi di produzione BAM-1 per la produzione commerciale, segnando una transizione dallo sviluppo a un vero focus produttivo.
Kraig Biocraft Laboratories (OTCQB: KBLB) anuncia la casi finalización de su mayor lote de producción de gusanos de seda de la línea parental BAM-1. Este hito marca el logro de verdaderos niveles de producción a escala comercial de la cepa parental. El lote actual está en fase de capullo esta semana, y el equipo de producción informa un fuerte crecimiento y una gran salud de la colonia.
El CEO Kim Thompson afirma que este ciclo de producción proporcionará el mayor suministro de huevos híbridos de producción BAM-1 en la historia de la empresa. Este éxito verifica la escalabilidad de la tecnología de seda de araña de Kraig Labs, posicionando a la empresa para entregar cantidades comerciales a socios y clientes. Los resultados suministrarán a Kraig Labs millones de híbridos de producción BAM-1 para la producción comercial, marcando una transición del desarrollo a un verdadero enfoque productivo.
Kraig Biocraft Laboratories (OTCQB: KBLB)가 BAM-1 부모 라인의 거미 줄기의 가장 큰 생산 배치가 거의 완료되었다고 발표했습니다. 이 이정표는 부모 균주 생산의 진정한 상업적 규모 수준을 달성했음을 나타냅니다. 현재 배치는 이번 주에로 고치를 짓고 있으며, 생산팀은 강력한 성장과 훌륭한 집단 건강을 보고하고 있습니다.
CEO 킴 톰슨은 이번 생산 주기가 회사 역사상 BAM-1 생산 하이브리드 알의 최대 공급을 제공할 것이라고 밝혔습니다. 이 성공은 Kraig Labs의 거미 실크 기술의 확장 가능성을 검증하며, 회사를 파트너와 고객에게 상업적 양을 제공할 수 있는 위치에 놓이게 합니다. 이 결과는 Kraig Labs에 상업 생산을 위한 수백만 개의 BAM-1 생산 하이브리드를 공급하여 개발에서 진정한 생산 중심으로의 전환을 의미합니다.
Kraig Biocraft Laboratories (OTCQB: KBLB) annonce l'achèvement imminent de son plus grand lot de production de vers à soie de la lignée parentale BAM-1. Cette étape marque l'atteinte de vrais niveaux de production commerciale de la souche parentale. Le lot actuel est en train de cocooner cette semaine, avec l'équipe de production signalant une forte croissance et une excellente santé de la colonie.
Le PDG Kim Thompson déclare que ce cycle de production fournira le plus grand approvisionnement d'œufs hybrides de production BAM-1 de l'histoire de l'entreprise. Ce succès vérifie la scalabilité de la technologie de soie d'araignée de Kraig Labs, positionnant l'entreprise pour délivrer des quantités commerciales à ses partenaires et clients. Les résultats fourniront à Kraig Labs des millions d'hybrides de production BAM-1 pour la production commerciale, marquant une transition du développement à un véritable axe de production.
Kraig Biocraft Laboratories (OTCQB: KBLB) kündigt den nahezu abgeschlossenen größten Produktionsbatch der BAM-1-Elternlinie-Spinnenseide-Seidenspinner an. Dieser Meilenstein markiert die Erreichung von echten kommerziellen Produktionsniveaus der Elterntyp-Produktion. Der aktuelle Batch ist diese Woche im Kokon, wobei das Produktionsteam ein starkes Wachstum und eine hervorragende Koloniegeme Gesundheit berichtet.
CEO Kim Thompson erklärt, dass dieser Produktionszyklus die größte Menge an BAM-1-Hybrideiern in der Unternehmensgeschichte bereitstellen wird. Dieser Erfolg bestätigt die Skalierbarkeit der Spinnenseidentechnologie von Kraig Labs und positioniert das Unternehmen, um kommerzielle Mengen an Partner und Kunden zu liefern. Die Ergebnisse werden Kraig Labs mit Millionen von BAM-1 Produktionshybriden für die kommerzielle Produktion versorgen, was einen Übergang von der Entwicklung zu einem echten Produktionsfokus markiert.
- Largest-ever production batch of BAM-1 parental line spider silk silkworms
- Achievement of commercial-scale levels of parental strain production
- Strong growth and great colony health reported in current production cycle
- Transition from development to true production focus
- Millions of BAM-1 production hybrids slated for commercial production
- None.
This Milestone marks the Achievement of True Commercial-scale Levels of Parental Strain Production
ANN ARBOR, Mich., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), the leading developer of commercially viable spider silk, is excited to announce that its current production batch is cocooning this week. This batch is the largest-scale production run of the BAM-1 parental lines in the Company's history.
This latest batch of silkworms is part of the Company’s ongoing expansion of its proprietary spider silk production technologies. The Company's production team and sericulture experts have been closely monitoring this production cycle and have reported strong growth and great colony health as Kraig Labs begins the cocooning process.
"We are very pleased with the progress of our current production cycle, which is on track to deliver the largest supply of BAM-1 production hybrid eggs in the Company's history," said Kim Thompson, CEO and founder of Kraig Labs. "The results we are seeing reflect our team's dedication to delivering truly cost-effective and commercially scalable spider silk production. This is a major step forward in commercializing spider silk technology, made possible by our new production center, and we look forward to utilizing this expanded production space to continue accelerating our plans for market entry."
The Company’s silkworms have been genetically engineered to produce recombinant spider silk at a level of efficiency and cost-effectiveness that was previously unattainable. This latest production run verifies the scalability of the Company's spider silk technology, positioning Kraig Labs to deliver commercial quantities of spider silk to its partners and customers.
With the near completion of this major production run, Kraig Labs has transitioned from a development and testing mindset to a true production focus. The results of this run will supply Kraig Labs with millions of BAM-1 production hybrids slated for commercial production.
"We are at an exciting and pivotal moment in Kraig Labs' history," Thompson added. "This successful production cycle is a testament to the hard work of our team and the power of our spider silk technologies. It underscores our commitment to unlocking the full potential of spider silk as an innovative material with limitless applications."
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What milestone did Kraig Biocraft Laboratories (KBLB) recently achieve in spider silk production?
How many BAM-1 production hybrids will Kraig Biocraft Laboratories (KBLB) have for commercial production?
What does the recent production milestone mean for Kraig Biocraft Laboratories' (KBLB) business focus?
What is the significance of the BAM-1 parental line for Kraig Biocraft Laboratories (KBLB)?
